Study Explores Patient Preferences in Second-Line RA Treatment Options

January 23rd 2021, 11:45am


Patients with rheumatoid arthritis (RA) were asked their preferences of second-line treatment options such as biologics and Janus kinase inhibitors, taking into account such factors as the probability of severe side effects, treatment effectiveness, administration route, and more.

Tocilizumab, Sarilumab Reduce Mortality Rates in Those Severely Ill With COVID-19

January 21st 2021, 10:00pm


Treatment with interleukin-6 receptor antagonists tocilizumab and sarilumab resulted in improved outcomes, including survival, among critically ill patients with coronavirus disease 2019 (COVID-19) receiving organ support in intensive care.

Machine Learning Identifies Patient Response to Sarilumab in Rheumatoid Arthritis

January 15th 2021, 10:30pm


Machine learning identified patients with rheumatoid arthritis who may have an increased chance of achieving clinical response with sarilumab, with those selected also showing an inferior response to adalimumab.

Switching From IV to SC IL-6 Receptor Inhibitor Therapy Shows No New Safety Signals

January 14th 2021, 9:46pm


The researchers say their new results can ease the concerns physicians or patients have when weighing the decision to switch route of administration for rheumatoid arthritis treatment.

Investigation Explores Relationship Between Psoriasis and Autoimmune Disorders

January 7th 2021, 10:15pm


Patients with psoriasis may be more likely to have additional autoimmune disorders, including vitiligo, diabetes, autoimmune thyroiditis, rheumatoid arthritis, and inflammatory bowel disease.

Study Investigates Role of Temperature in RA Activity

January 3rd 2021, 11:00am


Previous studies have shown conflicting characteristic thermographic patterns of the feet in patients with active rheumatoid arthritis (RA). This study probed whether the thermal characteristics of the feet of patients in remission differ to those of healthy controls.

Dementia in Patients With RA Lower in Those Using Biologics, Study Says

January 2nd 2021, 11:45am


Previous studies have suggested that inflammatory diseases such as rheumatoid arthritis (RA) can increase the risk for dementia and that tumor necrosis factor agents may have a role in preventing the incidence of dementia.

Immunosuppressive Drugs for Autoimmune Disease May Reduce Risk of ARDS in COVID-19 Hospitalizations

December 27th 2020, 12:45pm


Immunosuppressed patients who had an autoimmune disease (AD) were significantly less likely to develop severe acute respiratory distress syndrome (ARDS) compared with patients who were not immunosuppressed and did not have an AD.

Patients With Systemic Lupus Erythematosus Have Higher Cardiometabolic Risk for CVD

December 21st 2020, 3:48pm


Researchers explored the risk of cardiovascular disease (CVD) as it relates to factors like excess weight, disease evolution time, and clinical activity.

Sarilumab Shows Greater Improvements in QoL for Patients With RA and High Levels of IL-6

December 18th 2020, 10:02pm


Compared with adalimumab, sarilumab elicited greater improvements in health-related quality of life (QoL), particularly in patients with high levels of interleukin-6 (IL-6).